~~<i id='8132B14BE7'><strike id='8132B14BE7'><tt id='8132B14BE7'><pre id='8132B14BE7'></pre></tt></strike></i>~~

Home» Wikipedia» Wikipedia

Wikipedia

author：fashion 2025-09-30 04:11:27 Page View：48

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Adam's Take: Intra
Next article： Sports medicine is finally prioritizing gender equality

explore

The high cost of giving birth even with insurance

AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul

Erich Jarvis studies song birds to learn about human stuttering

Starlingsperchonapowerlineinthemorningsun.PATRICKPLEUL/DPA/AFPviaGettyImagesAsymphonyofsynapsesfires

Wildfire smoke exposes gaps in outdoor worker protections

ApersonwaitingforthesubwaywearsafilteredmaskassmokyhazefromwildfiresinCanadablanketsaneighborhoodinN

Asbestos ban is immediate, but health effects will linger for decades

BrookMitchell/GettyImagesAnewruleannouncedbytheEnvironmentalProtectionAgencythisweekputsanendtotheus